Richard Sandler, MD
Nephrology · Plantation, FLNPI 1720009376
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $211 of the $236 with a category attached, or 89.6%. 4 manufacturers reported payments, led by Akebia Therapeutics Inc at 49.9% of the total. Reporting peaked in 2019 at $93 and has fallen 73.6% since, to $25 in 2024. That places this record below the midpoint for nephrology clinicians in FL, where the typical reported total is $1,407.
Across 10 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$118
- GSK$61
- Vifor Pharma, Inc.$41
- Amgen$17
Across 155 payments — averaging $1108.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$170K
- GSK$2K
What the payments were for
- Food & beverage$21190%
- Education$2510%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 5 | $118 |
| GSK | 2 | $61 |
| Vifor Pharma, Inc. | 2 | $41 |
| Amgen | 1 | $17 |
How this compares
$236 in reported general payments places this provider in the 15th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 112 | $93,822 |
| EliquisApixaban | 31 | $25,919 |
| Sevelamer Carbonate | 56 | $9,785 |
| Repatha SureclickEvolocumab | 13 | $7,331 |
| Pentoxifylline | 112 | $7,138 |
| Calcium Acetate | 97 | $5,668 |
| SynthroidLevothyroxine Sodium | 44 | $5,522 |
| SpsSodium Polystyrene Sulfon/Sorb | 25 | $3,595 |
| Candesartan Cilexetil | 54 | $3,219 |
| Calcitriol | 119 | $3,143 |
| Allopurinol | 125 | $2,155 |
| Ezetimibe | 75 | $1,931 |
| Midodrine Hcl | 23 | $1,775 |
| Rosuvastatin Calcium | 102 | $1,570 |
| Nifedipine ErNifedipine | 44 | $1,088 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Plantation
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
- Fouad ChebibJacksonville$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.